PROTHENA CORP PUBLIC LTD CO (PRTA) Form 8-K — Aug 6, 2026
Prothena reported a second quarter 2026 net loss of $18.6 million, a sharp improvement from a $125.8 million net loss in the year-ago quarter, on total revenue of $1.0 million versus $4.4 million a year earlier. For the first six months of 2026 the company posted net income of $14.1 million, driven primarily by a $50.0 million milestone payment from Novo Nordisk tied to the Phase 3 CLEOPATTRA trial of coramitug. The company ended the quarter with $289.1 million in cash, cash equivalents and restricted cash, no debt, and approximately 51.3 million ordinary shares outstanding as of July 30, 2026.
Key figures
- Revenue
- 1010000
- Guidance
- FY2026 net cash used in operating and investing activities of $18-23 million; year-end 2026 cash, cash equivalents and restricted cash of approximately $259 million (midpoint), lowered $14 million from prior $273 million midpoint, primarily due to ~$12 million of share repurchases; estimated FY2026 net loss of $25-30 million including ~$26 million non-cash share-based compensation
- Total Debt
- 0
- Total Assets
- 302579000
- Cash Position
- 289100000
- Shares Outstanding
- 51300000
- Q2 2025 rd expense
- 40517000
- Q2 2026 ga expense
- 10899000
- Q2 2026 rd expense
- 8798000
- Buyback 1h2026 spend
- 22300000
- Buyback 1h2026 shares
- 2243888
- Buyback authorization
- 100000000
- First half 2026 revenue
- 52094000
- First half 2026 net income
- 14138000
- Prx019 milestone potential
- 55000000
- Q2 2026 restructuring expense
- 2414000
- Potential partnered milestones
- 3000000000
- Novo nordisk milestone received
- 50000000
- Novo nordisk attr acquisition value
- 1200000000
- Prior ye2026 cash guidance midpoint
- 273000000
- Roche peak sales potential prasinezumab
- 3500000000
Price after filing
Close on the filing date to close N calendar days later (from $8.49). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.